2023-04-12 14:50:38 ET
- X4 Pharmaceuticals ( NASDAQ: XFOR ) added ~22% on Wednesday, marking the biggest intraday gain in over six months after announcing upcoming data readouts for its lead candidate mavorixafor in rare immune disease WHIM syndrome.
- The company said that new data from a Phase 3 program for the candidate would be presented at the Annual Meeting of the Clinical Immunology Society (CIS), scheduled to take place in St. Louis, MO, from May 18 to May 21, 2023.
- The company plans to conduct a virtual event before the meeting on May 16 to discuss new data from its 4WHIM Phase 3 clinical trial after the publication of conference abstracts.
- Announcing topline data from 4WHIM in November, XFOR said that the study met its primary endpoint and a key secondary endpoint with no treatment-related serious adverse events and no discontinuations related to safety events.
- Read: Issuing a Strong Buy on X4 Pharmaceuticals ( XFOR ), Seeking Alpha analyst Frugal Norwegian argued on Wednesday that the XFOR stock “is at an all-time low and appears poised for a rebound.”
For further details see:
X4 Pharma jumps 22% on upcoming data readout for lead asset